FTC Admin. Judge Says Endo-Impax Opana Deal Is Lawful
A patent deal in which Endo Pharmaceuticals Inc. paid generic-drug maker Impax Laboratories Inc. to forgo launching a generic version of an opioid pain medication did not violate consumer protection statutes,...To view the full article, register now.
Already a subscriber? Click here to view full article